Compare Divis Laboratories with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs NATCO PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES NATCO PHARMA DIVIS LABORATORIES/
NATCO PHARMA
 
P/E (TTM) x 59.2 34.0 174.3% View Chart
P/BV x 13.6 4.8 282.5% View Chart
Dividend Yield % 0.4 0.7 64.1%  

Financials

 DIVIS LABORATORIES   NATCO PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
NATCO PHARMA
Mar-19
DIVIS LABORATORIES/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,639849 193.1%   
Low Rs1,115557 200.2%   
Sales per share (Unadj.) Rs186.3573.8 32.5%  
Earnings per share (Unadj.) Rs51.0176.0 29.0%  
Cash flow per share (Unadj.) Rs57.3198.2 28.9%  
Dividends per share (Unadj.) Rs16.006.25 256.0%  
Dividend yield (eoy) %1.20.9 130.7%  
Book value per share (Unadj.) Rs261.8842.7 31.1%  
Shares outstanding (eoy) m265.4736.50 727.3%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x7.41.2 603.3%   
Avg P/E ratio x27.04.0 676.6%  
P/CF ratio (eoy) x24.03.5 677.4%  
Price / Book Value ratio x5.30.8 630.7%  
Dividend payout %31.43.6 884.2%   
Avg Mkt Cap Rs m365,59225,660 1,424.8%   
No. of employees `00011.85.0 239.0%   
Total wages/salary Rs m5,4233,559 152.4%   
Avg. sales/employee Rs Th4,175.14,225.3 98.8%   
Avg. wages/employee Rs Th457.7718.0 63.8%   
Avg. net profit/employee Rs Th1,141.81,295.9 88.1%   
INCOME DATA
Net Sales Rs m49,46320,945 236.2%  
Other income Rs m1,5561,302 119.5%   
Total revenues Rs m51,01922,247 229.3%   
Gross profit Rs m18,7187,948 235.5%  
Depreciation Rs m1,689810 208.5%   
Interest Rs m35193 18.1%   
Profit before tax Rs m18,5518,247 224.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0231,823 275.6%   
Profit after tax Rs m13,5276,424 210.6%  
Gross profit margin %37.837.9 99.7%  
Effective tax rate %27.122.1 122.5%   
Net profit margin %27.330.7 89.2%  
BALANCE SHEET DATA
Current assets Rs m46,50123,472 198.1%   
Current liabilities Rs m8,4687,287 116.2%   
Net working cap to sales %76.977.3 99.5%  
Current ratio x5.53.2 170.5%  
Inventory Days Days13192 141.9%  
Debtors Days Days8688 97.3%  
Net fixed assets Rs m25,79718,648 138.3%   
Share capital Rs m531365 145.5%   
"Free" reserves Rs m68,96234,525 199.7%   
Net worth Rs m69,49330,760 225.9%   
Long term debt Rs m00-   
Total assets Rs m80,38343,031 186.8%  
Interest coverage x531.043.7 1,214.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.5 126.4%   
Return on assets %16.915.4 109.7%  
Return on equity %19.520.9 93.2%  
Return on capital %26.727.4 97.5%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23811,536 357.5%   
Fx outflow Rs m12,4052,939 422.1%   
Net fx Rs m28,8338,597 335.4%   
CASH FLOW
From Operations Rs m9,5436,688 142.7%  
From Investments Rs m-6,854-6,122 112.0%  
From Financial Activity Rs m-2,459-509 483.2%  
Net Cashflow Rs m23066 347.9%  

Share Holding

Indian Promoters % 52.0 52.0 99.9%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 11.8 7.8 150.5%  
FIIs % 19.0 16.6 114.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 26.0 66.2%  
Shareholders   31,796 25,395 125.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SHASUN PHARMA  WYETH  GSK PHARMA  SUVEN LIFE SCIENCES  DR. REDDYS LAB  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 25, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS